Serum levels of interleukin 10 (IL-10) in patients with type 2 diabetes

Iranian Red Crescent Medical Journal

Volumn 13, Issue 10, 2011, Pages 751-752

  Yaghini, N ^a   Mahmoodi, M ^a   Asadikaram, Gh R ^a   Hassanshahi, Gh H ^a   Khoramdelazad, H ^a   Kazemi Arababadi, M ^a  

^a RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Interleukin 10; Type 2 diabetes

Indexed keywords

INTERLEUKIN 10;

BLOOD ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; LETTER; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL;

EID: 80755163667     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Steyn NP, Lambert EV, Tabana H. Nutrition interventions for the prevention of type 2 diabetes. Proc Nutr Soc 2008;10:1-16.
2. Giulietti A, van Etten E, Overbergh L, Stoffels K, Bouillon R, Mathieu C. Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory. Diabetes Res Clin Pract 2007;77:47-57. [17112620] [http://dx.doi.org/10.10 16/j.diabres.2006.10.007]
3. Bartosik-Psujek H, Stelmasiak Z. The interleukin-10 levels as a potential indicator of positive response to interferon beta treatment of multiple sclerosis patients. Clin Neurol Neurosurg 2006;108:644-7. [16343740] [http://dx.doi.org/10.1016/j.clineuro.2005.10.011]
4. Jana M, Pahan K. IL-12 p40 homodimer, but not IL-12 p70, induces the expression of IL-16 in microglia and macrophages. Mol Immunol 2009;46:773-83. [19100623] [http://dx.doi.org/10.1016/j.molimm.2 008.10.033]
5. Araya C, Diaz L, Wasserfall C, Atkinson M, Mu W, Johnson R, Garin E. T regulatory cell function in idiopathic minimal lesion nephrotic syndrome. Pediatr Nephrol 2009;24: 1691-8. [19495805] [http://dx.doi. org/10.1007/s00467-009-1214-x]
6. Lin CY, Chien JW. Increased interleukin-12 release from peripheral blood mononuclear cells in nephrotic phase of minimal change nephrotic syndrome. Acta Paediatr Taiwan 2004;45:77-80. [15335115]
7. Lee M, Park H, Youn J, Oh ET, Ko K, Kim S, Park Y. Interleukin-10 plasmid construction and delivery for the prevention of type 1 diabetes. Ann N Y Acad Sci 2006; 1079:313-9. [17130572] [http://dx. doi.org/10.1196/annals.1375.048]
8. Wegner M, Winiarska H, Bobkiewicz-Kozlowska T, Dworacka M. IL-12 serum levels in patients with type 2 diabetes treated with sulphonylureas. Cytokine 2008;42:312-6. [18397831] [http://dx.doi.org/10. 1016/j.cyto.2008.02.014]
9. Bagavant H, Fu SM. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr Opin Rheumatol 2009;21:489-94. [19584729] [http://dx.doi.org/10.1097/BOR.0b01 3e32832efff1]
10. van Exel E, Gussekloo J, de Craen AJ, Frölich M, Bootsma-Van Der Wiel A, Westendorp RG; Leiden 85 Plus Study. Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes: the Leiden 85-Plus Study. Diabetes 2002;51:1088-92. [119169 30] [http://dx.doi.org/10.2337/diabetes.51.4.1088]